Chol-CTPP

• UNSPSC Description:

  Chol-CTPP is a ligand with dual targeting effect on blood-brain barrier (BBB) and glioma cells. Lip-CTPP can be gained by Chol-CTPP and another mitochondria targeting ligand (Chol-TPP). Lip-CTPP is a promising potential carrier to exert the anti-glioma effect of doxorubicin (DOX) and lonidamine (LND) collaboratively. Lip-CTPP elevates the inhibition rate of tumor cell proliferation, migration and invasion, promote apoptosis and necrosis, and interfere with mitochondrial function[1].

• Target Antigen:

  Apoptosis; Reactive Oxygen Species

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/chol-ctpp.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=CC=C(C=C1)O)NCCOCCNC(C(CCCC2)=C2C(NCCCCCC(OCCO[C@@H](CC3)CC4=CC[C@]([C@@]5([H])[C@](CC6)([C@@](CC5)([H])[C@H](C)CCCC(C)C)C)([H])[C@@]6([H])[C@]43C)=O)=O)=O.[3].[44]

• Molecular Weight:

  2884.62

• References & Citations:

  [1]Jiaqi Lu, et al. Multiple targeted doxorubicin-lonidamine liposomes modified with p-hydroxybenzoic acid and triphenylphosphonium to synergistically treat glioma. Eur J Med Chem. 2022 Feb 15;230:114093.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported